ANAB · AnaptysBio, Inc.
$54.15
-2.80% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
10.2
Dividend yield
—
Beta
0.38
Avg volume
1M
Employees
0K
2D change
-1.00%
5D change
-2.37%
10D change
-7.57%
30D change
-15.11%
60D change
-3.70%
MTD change
-18.07%
YTD change
65.87%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ANAB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-13
Latest call per bank · past 12 months
UBS
Buy$76.00
+40.4% vs priceBarclays
Overweight$75.00
+38.5% vs priceWells Fargo
Overweight$81.00
+49.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-13 | UBS | Maintains | Buy | $60.00 → $76.00 |
| 2026-05-13 | Barclays | Maintains | Overweight | $63.00 → $75.00 |
| 2026-05-04 | Piper Sandler | Maintains | Overweight | $95.00 → $93.00 |
| 2026-04-28 | Leerink Partners | Maintains | Outperform | $66.00 → $85.00 |
| 2026-04-22 | Barclays | Maintains | Overweight | $79.00 → $63.00 |
| 2026-04-21 | UBS | Maintains | Buy | $90.00 → $60.00 |
| 2026-03-31 | Piper Sandler | Maintains | Overweight | $67.00 → $95.00 |
| 2026-03-30 | HC Wainwright & Co. | Reiterates | Buy | $66.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 10.6% below the 50-day MA ($58.31).
- Price vs 200-day MA: Trading 25.3% above the 200-day MA ($41.60).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.23) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.93) and high ($69.81).
ANAB Price Chart
Loading chart for ANAB…
Fundamentals
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.